![](/assets/default_company_panoramic_image-25937d8eab89e89a7dc30165ae221f7d4020dd13520c1d30da88bbbea34367f7.png)
![](https://gust-production.s3.amazonaws.com/uploads/startup/placeholder_logo_image/116229/00a8d5f2-b8c8-47bc-a739-d1c4c7700e61.png)
Hurel Corporation
Hurel is a private, revenue-generating medtech company that uses cell biology and microfluidics to help drug companies predict early (i.e., pre-clinically) the
- Stage $1M in TTM Revenue
- Industry Biotechnology
- Location New Brunswick, NJ, USA
- Currency USD
- Employees 6
- Website hurelcorp.com
Company Summary
- Hurel Corporation utilizes cell biology and microfluidics to better predict the effects of pharmaceuticals and chemicals on the human body.
- Hurel’s patented, in vitro testing platforms provide superior means to evaluate the performance of a drug in humans before researchers make the costly, risky decision whether or not to invest in human clinical trials.
- Recognized as a highly promising alternative to animal testing.
Team
-
Robert M. FreedmanChairman and CEO
Robert M. Freedman, Chairman & CEO, has piloted Hurel through its early development to
the launch of its first commercial product. Previously he was a member of the venture capital
firms BancBoston Ventures & Wolfensohn Partners. He was also a First Vice President in the
firm Drexel Burnham Lambert. Rob holds an SB Degree from MIT and
Masters’ Degrees from the Kennedy School of Government at Harvard and (with honors) from Harvard Business Sch -
Martin Yarmush, M.D., Ph.D.Chief Scientific Advisor
Internationally known engineer of cell cultures in microfluidic systems. Founder/Director, Center for Engineering in Medicine, Massachusetts General Hospital. Founder/Professor, School of Biomedical engineering, Rutgers. Ph.D., Rockefeller (biophysical chemistry); Ph.D., MIT (chemical engineering); M.D., Yale
-
James MacDonald, Ph.D., DABTDirector of Corporation
Formerly EVP of pre-clinical development, Schering-Plough. Has taken hundreds of drug candidates into development, >30 of which have become major drugs. Ph.D., University of Cincinnati.
-
Laura DikeHead of Operations
Formerly Operations Manager, BD Biosciences, 10 years' experience in Biotech R&D/Operations management. Expertise in hepatocyte culture, DMPK, cellular assay systems, GLP. BA, Wellesley; Ph.D., Boston University School of Medicine. (to be employed upon completion of financing)
-
Leslie Z. Benet, Ph.D.Scientific Advisory Board Chairman
Professor and former Chairman, Department of Pharmaceutical Sciences, UCSF. Founder and first President, American Association of Pharmaceutical Scientists. Member, Institute of Medicine; seven doctorates honoris causa. Most widely cited pharmacokineticist in the world. SB and MS, University of Rochester; Ph.D., UCSF.
-
Eric NovikChief Technology Officer
Laboratory expert in Hurel Static- and Hurel Flow-based systems; advanced tissue culture, stem cells, DMPK and tox assays and applications. Ph.D. (biomedical engineering), Rutgers University
Advisors
-
Dykema Gossett PLLC, Los Angeles (Corporate Securities); Arrigo And Scott Lee, LLP, Washington D.C. (IP)LawyerUnconfirmedGaytan & Leevan, LLP, Los AngelesAccountantUnconfirmed
Previous Investors
-
- seed investor: Athena Capital Partners, LLC.Unconfirmed- convertible notes: aggregate face value $1,085k issued to accredited individualUnconfirmedinvestors in amounts up to $200k each.Unconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.